NIH-funded research R01 grant

Which blood‑pressure drug during major surgery better protects the kidneys

Official title: The choice of vasopressor to prevent postoperative acute kidney injury after major non-cardiac surgery: a multicenter pragmatic cluster cross-over randomized trial (the VEGA-2 trial)

Funded at University of California, San Francisco · NIH-11176032 · Data updated 2026-11-12

This compares two common medicines given for low blood pressure during major non‑cardiac surgery to find which one best prevents sudden kidney injury in adults.

More Acute Kidney Injury research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Francisco
NIH-funded
Lab location1 site (San Francisco, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2029
Funding year2025
Award (this year)$671,176
NIH project number5R01DK139484-02
Project IDNIH-11176032 on NIH RePORTER

Who could benefit from this research

Could help

Adults (including older adults) undergoing major non‑cardiac surgery who may need intravenous vasopressors for low blood pressure during the operation are the ideal candidates.

Less likely to help

People not having major non‑cardiac surgery, those who do not require intraoperative vasopressors, and children are unlikely to benefit from participating.

What this research studies

If you are an adult having major non‑cardiac surgery, hospitals in this trial will use one of two commonly used blood‑pressure drugs when treating low blood pressure in the operating room. Hospitals take turns using norepinephrine or phenylephrine across different time periods so patients receive whichever drug is the hospital's current protocol. The trial is pragmatic and embedded in routine care across multiple centers, and researchers will track who develops postoperative acute kidney injury and related outcomes after surgery. Results will compare kidney outcomes and other complications between the two drugs to inform which choice is safer for patients.

Why it matters

Potential benefit: If successful, this could lower the chance of developing acute kidney injury after major surgery and reduce related complications and hospital stays.

How similar studies have gone: Some smaller trials and observational studies have hinted at differences between these drugs for kidney outcomes, but large randomized evidence is still needed.

Where this research is happening

  • University of California, San Francisco
    San Francisco, United States
    Active

Researchers

  • Principal investigator: Legrand, Matthieu — University of California, San Francisco
  • Study coordinator: Legrand, Matthieu

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.